Glucotrack
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 6
- Market Cap
- -
- Introduction
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose Sensor
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Glucotrack
- Target Recruit Count
- 10
- Registration Number
- NCT06764069
- Locations
- 🇧🇷
Instituto do Coração (InCor) |, São Paulo, Brazil
News
Glucotrack Secures Ethical Approval for Long-Term Clinical Study of Implantable Blood Glucose Monitor
Glucotrack has received ethical approval from St. Vincent's Hospital Melbourne HREC for a year-long clinical study of its implantable continuous blood glucose monitor in patients with type 1 and type 2 diabetes.
Glucotrack Advances to Clinical Stage with Innovative Implantable Continuous Blood Glucose Monitor
Glucotrack has successfully transitioned from preclinical to clinical stage in 2024, completing its first human clinical study of a fully implantable continuous blood glucose monitoring (CBGM) system with promising results.
Glucotrack Completes First Human Trial of Novel Implantable Blood Glucose Monitor
Glucotrack successfully completed its first-in-human clinical study of a continuous blood glucose monitor implanted in the subclavian vein, with no serious adverse events reported.